Olson BM, Frye TP, JohnsonLE, Fong L, Knutson KL, Disis ML, McNeel DG. HLA-A2-Restricted T-Cell Epitopes Specific for Prostatic Acid Phosphatase. Cancer Immunol Immunother, 59(6):943-53, 2010.

Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. Phase I clinical trial of the CYP 17 inhibitor abiraterone acetate (CB7630), Demonstrating clinical activity in castration-resistant prostate cancer patients with prior ketoconazole therapy. J Clin Oncol, 28:1481-1488, 2010.

Cha E, Fong L. Therapeutic Vaccines for Prostate Cancer. Curr Opin Mol Ther, 1: 77-85, 2010.

Shum AK, DeVoss J, Tan CL, Hou Y, Johannes K, O’Gorman CS, Jones KD, Sochett EB, Fong L, Anderson MS. Identification of an autoantigen demonstrates a link between interstitial lung disease and a defect in central tolerance. Science- Transl Med, 1:9ra20, 2009.

Chien AJ, Illi JA, Ko A, Korn W, Fong L, Chen L, Kashani-Sabet M, Ryan C, Rosenberg J, Dubey S, Small E, Jahan T, Hylton N, Yeh B, Huang Y, Koch K, Moasser MM. A phase 1 study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound paclitaxel for advanced solid malignancies. Clin Can Res 17: 5569-5575, 2009.

Hou Y, Devoss J, Dao V, Kwek SS, Simko J, McNeel D, Anderson MS, Fong L. An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. J Clin Invest 119: 2031-2041, 2009.

Fong L, Kwek SS, O’Brien S, Kavanagh B, Weinberg V, Lin A, Rosenberg J, Ryan CJ, McNeel D, Rini B, Small EJ. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 69, 609-615, 2009.

Fong L, Small EJ. Anti-CTLA4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26(32) 5275-5283, 2008.

Kavanagh B, O’Brien S, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependant fashion. Blood 112(4):1175-83, 2008.

Fasso M, Waitz R, Rim T, Hou Y, Greenberg NM, Shastri N, Fong L, Allison JP. SPAS-1 (stimulator of prostatic adenocarcinoma specific T cells-1)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci 105(9):3509-14, 2008.

Hou Y, Kavanagh B, Fong L. Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. J Immunol 180(3):1526-34, 2008.

Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ. Phase II study of ketoconazole plus GM-CSF in hormone refractory prostate cancer: Effect of extent of disease on outcome. J Urol 178(6):2372-6, 2007.

Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Shilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunoth 30(7):762-772, 2007.

Fong L, Small EJ. Immunotherapy for prostate cancer. Curr Oncol Rep 9(3):226-33, 2007.

Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer. Clin Cancer Res 13(6):1810-5, 2007.

Devoss J, Hou Y, Johannes K, Lu W, Liou GI, Rinn J, Chang H, Caspi R, Fong L, Anderson MS. Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. J Exp Med 203(12):2727-35, 2006.

Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 98(4):763-9, 2006.

Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, and Wilding G, A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen-Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer. Mol Ther 14(1):107-17, 2006.

Rini BI, Weinberg V, Fong L, Conry S, Hershberg R, and Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 107(1):67-74, 2006.

Rini BI, Fong L, Weinberg V, Kavanagh B, Small EJ. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J Urol 175(6):2087-91, 2006.

Fong L, Small EJ. Immunotherapy for prostate cancer. Curr Urol Rep 7(3):239-46, 2006.

Kapadia D, Fong L. CTLA4 blockade: Autoimmunity as treatment. J Clin Oncol 23(35):8926-8, 2005.

Fong L. Small EJ. Immunotherapy for prostate cancer. Sem Oncol 30(5): 649-658, 2003.

Engleman EG, Fong L. Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients. Clin Immunol 106(1):10-5, 2003.

Fong L, Mengozzi M, Abbey NW, Herndier BG, Engleman EG. Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligation. J Virol 76(21):11033-41, 2002.

Merad M, Sugie T, Engleman EG, Fong L. In vivo manipulation of dendritic cells to induce therapeutic antitumor immunity. Blood 99(5):1676-82, 2002.

Fong L, Benike C, Strang G, Smits B, Ruegg CL, Engleman EG. Immunotherapy with xenoantigen loaded dendritic cells in prostate cancer patients. J Immunol 167: 7150-7156, 2001.

Fong L, Hao Y, Rivas A, Benike C, Yuen A, Fisher G, Davis MM, Engleman EG. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci 98(15):8809-14, 2001.

Fong L, Brockstedt DG, Benike C, Wu L, Engleman EG. Induction of immunity with dendritic cells administered via different routes in cancer patients. J Immunol 166: 4254-4259, 2001.

Merad M, Fong L, Bogenberger J, Engleman EG. Differentiation of myeloid dendritic cells into CD8α-positive dendritic cells in vivo. Blood 96(5):1865-72, 2000.

Fong L and Engleman EG. Dendritic cells in cancer immunotherapy. Ann Rev Immunol 18:245-273, 2000.

Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5(6):677-685, 1999.

Brockstedt DG, Podsakoff GM, Fong L, Kurtzman G, Mueller-Ruchholtz W, Engleman EG. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol 92(1):67-75, 1999.

Hayamizu K, Zeng D, Huie P, Garcia-Ojeda ME, Bloch DA, Fong L, Engleman EG, Sibley RK, Strober S. Donor blood monocytes but not T or B cells facilitate long-term allograft survival after total lymphoid irradiation. Transplantation 66(5):585-93, 1998.

Fong L, Ruegg C, Brockstedt DG, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: Implications for prostate cancer immunotherapy. J Immunol 159:3113-3118, 1997.

Kim DT, Mitchell D, Brockstedt DG, Fong L, Nolan GP, Fathman CG, Engleman EG, Rothbard JB. Introduction of soluble proteins into both MHC class I and II pathways by conjugation to a HIV tat peptide. J Immunol 159:1666-68,1997.